Intercytex Lauches New Cell2Therapy Initiative
28 Nov 2011
Intercytex has announced that they are offering their extensive expertise in bringing a variety of autologous and allogeneic cell therapies to the clinic in the US, UK and mainland Europe through their new Cell2Therapy service.
This is a contract translation service which can provide practical help in any or all the steps from product development, through regulatory approvals, GMP manufacture of the product and clinical trial operation. Depending on a client’s needs and commercial plans, Cell2Therapy can either take responsibility for these processes or mentor the client through the various stages themselves.
For more information, please see their website: www.Cell2Therapy.com.
